Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics Inc (SLNO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Why Soleno Therapeutics Stock Is Skyrocketing Today

The clinical-stage biotech company received great news from the FDA.

SLNO : 41.90 (-1.39%)
Why Soleno Therapeutics Stock Ticked Higher on Thursday

The latest pundit take on the stock provided a good reason for bulls to snap it up.

SLNO : 41.90 (-1.39%)
Why Shares of Soleno Therapeutics Dropped on Wednesday

Investors took profits a day after the clinical-stage biotech company's shares soared.

SLNO : 41.90 (-1.39%)
Shares of Soleno Therapeutics (NASDAQ: SLNO) Surge Over 500% After Its DCCR Candidate Shows Promise in PWS Clinical Trials

Breakthrough Results from Study C602 Soleno Therapeutics, Inc. (NASDAQ: SLNO), a trailblazer in the biopharmaceutical industry, recently unveiled its promising

SLNO : 41.90 (-1.39%)
Why Shares of Soleno Therapeutics Are Booming on Tuesday

Soleno announced positive top-line results for DCCR, its lead therapy.

SLNO : 41.90 (-1.39%)
Soleno Therapeutics, Inc. (SLNO) Upgraded to Strong Buy: What Does It Mean for the Stock?

Soleno Therapeutics, Inc. (SLNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

SLNO : 41.90 (-1.39%)
Three Healthcare Penny Stocks to Watch In The New Year

These three penny (and nickel) stocks in the healthcare sector have a lot of potential for 2023, and definitely worth watching.

ACRX : 0.8600 (+7.50%)
HAPP : 4.50 (+1.35%)
SLNO : 41.90 (-1.39%)
Pre-Market Brief: Stocks Mostly Lower as Economic Outlook Darkens, BoJ Policy Shift

March S&P 500 futures (ESH23) are trending down -0.08% this morning after three major U.S. benchmark indices closed lower for a fourth straight session, with Nasdaq dropping the most as market participants'...

ESH23 : 3,957.05s (-0.09%)
META : 499.49 (-1.41%)
ICCM : 0.7890 (+2.48%)
LCID : 2.57 (-1.53%)
SLNO : 41.90 (-1.39%)
TERN : 7.37 (-7.41%)
SMCI : 920.01 (+3.67%)
Catalyst Pharmaceuticals (CPRX) Rallies 80.69% YTD: Here's Why

Catalyst (CPRX) price rallies on FDA approval of the sNDA of its lead drug, Firdapse, approved to treat LEMS in patients above six years of age.

CPRX : 14.97 (-0.20%)
AERI : 15.25 (+0.07%)
SLNO : 41.90 (-1.39%)
ACER : 0.6601 (-17.95%)
Catalyst Pharma's (CPRX) sNDA for Firdapse Approved by the FDA

Catalyst Pharmaceuticals (CPRX) announces FDA approval of its sNDA for Firdapse to include pediatric patients for treating Lambert-Eaton myasthenic syndrome.

CPRX : 14.97 (-0.20%)
AERI : 15.25 (+0.07%)
SLNO : 41.90 (-1.39%)
ACER : 0.6601 (-17.95%)

Barchart Exclusives

Is This Industrial Stock a Buy After Its Latest Dividend Hike?
As this heavy machinery giant raises its quarterly payouts, should investors consider the industrial stock? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar